Purpose
Infection by the intracellular apicomplexan parasite
Toxoplasma gondii
has serious clinical consequences in humans and veterinarians around the world. Although about a third of the worldâs population is infected with
T. gondii
, there is still no effective vaccine against this disease. The aim of this study was to develop and evaluate a multimeric vaccine against
T. gondii
using the proteins calcium-dependent protein kinase (CDPK)1, CDPK2, CDPK3, and CDPK5.
Materials and Methods
Top-ranked major histocompatibility complex (MHC)-I and MHC-II binding as well as shared, immunodominant linear B-cell epitopes were predicted and linked using appropriate linkers. Moreover, the 50S ribosomal protein L7/L12 (adjuvant) was mixed with the constructâs N-terminal to increase the immunogenicity. Then, the vaccineâs physicochemical characteristics, antigenicity, allergenicity, secondary and tertiary structure were predicted.
Results
The finally-engineered chimeric vaccine had a length of 680 amino acids with a molecular weight of 74.66 kDa. Analyses of immunogenicity, allergenicity, and multiple physiochemical parameters indicated that the constructed vaccine candidate was soluble, non-allergenic, and immunogenic, making it compatible with humans and hence, a potentially viable and safe vaccine candidate against
T. gondii
parasite.
Conclusion
In silico
, the vaccine construct was able to trigger primary immune responses. However, further laboratory studies are needed to confirm its effectiveness and safety.